![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KD Burris, M Breeding and E Sanders-Bush
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Activation of central serotonin 5HT2 receptors is believed to be the primary mechanism whereby lysergic acid diethylamide (LSD) and other hallucinogens induce psychoactive effects. This hypothesis is based on extensive radioligand binding and electrophysiological and behavioral studies in laboratory animals. However, the pharmacological profiles of 5HT2 and 5HT1C receptors are similar, making it difficult to distinguish between effects due to activation of one or the other receptor. For this reason, it was of interest to investigate the interaction of LSD with 5HT1C receptors. Agonist-stimulated phosphoinositide hydrolysis in rat choroid plexus was used as a direct measure of 5HT1C receptor activation. (+)LSD potently stimulated phosphoinositide hydrolysis in intact choroid plexus and in cultures of choroid plexus epithelial cells, with EC50 values of 9 and 26 nM, respectively. The effect of (+)LSD in both systems was blocked by 5HT receptor antagonists with an order of activity consistent with interaction at 5HT1C receptors. Neither (+)-2-bromo-LSD nor lisuride, two nonhallucinogenic congeners of LSD, were able to stimulate 5HT1C receptors in cultured cells or intact choroid plexus. In contrast, lisuride, like (+)LSD, is a partial agonist at 5HT2 receptors in cerebral cortex slices and in NIH 3T3 cells transfected with 5HT2 receptor cDNA. The present finding that (+)LSD, but not its nonhallucinogenic congeners, is a 5HT1C receptor agonist suggests a possible role for these receptors in mediating the psychoactive effects of LSD.
This article has been cited by other articles:
|
|
 |
|
  S. Kaiser and L. K. Nisenbaum Evaluation of common gene expression patterns in the rat nervous system Physiol Genomics, December 16, 2003; 16(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Parker, J. R. Backstrom, E. Sanders-Bush, and B.-H. Shieh Agonist-induced Phosphorylation of the Serotonin 5-HT2C Receptor Regulates Its Interaction with Multiple PDZ Protein 1 J. Biol. Chem., June 6, 2003; 278(24): 21576 - 21583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cussac, A. Newman-Tancredi, D. Duqueyroix, V. Pasteau, and M. J. Millan Differential Activation of Gq/11 and Gi3 Proteins at 5-Hydroxytryptamine2C Receptors Revealed by Antibody Capture Assays: Influence of Receptor Reserve and Relationship to Agonist-Directed Trafficking Mol. Pharmacol., September 1, 2002; 62(3): 578 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chang, L. Zhang, J. P. Tam, and E. Sanders-Bush Dissecting G Protein-coupled Receptor Signaling Pathways with Membrane-permeable Blocking Peptides. ENDOGENOUS 5-HT2C RECEPTORS IN CHOROID PLEXUS EPITHELIAL CELLS J. Biol. Chem., March 15, 2000; 275(10): 7021 - 7029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Berg, S. Maayani, J. Goldfarb, C. Scaramellini, P. Leff, and W. P. Clarke Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus Mol. Pharmacol., July 1, 1998; 54(1): 94 - 104. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. R. Villalobos, J. T. Parmelee, and J. B. Pritchard Functional Characterization of Choroid Plexus Epithelial Cells in Primary Culture J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 1109 - 1116. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
